NCT03298438: NF1

Study About Annoucement of the Diagnosis of Neurofibromatosis 1 in de Novo Forms

Completed Last updated 2 October 2017

What this trial tests

trial in Neurofibromatosis 1 in 31 participants. Completed in 31 December 2016.

Timeline

15 July 2016

Primary endpoint
31 December 2016

31 December 2016

Quick facts

Lead sponsor	University Hospital, Brest
Status	Completed
Study type	OBSERVATIONAL
Enrollment	31
Start date	15 July 2016
Primary completion	31 December 2016
Estimated completion	31 December 2016
Sites	1 location across France

Conditions studied

• Neurofibromatosis 1 — all drugs for Neurofibromatosis 1 →
• Diagnoses Disease — all drugs for Diagnoses Disease →
• Post Traumatic Stress Disorder — all drugs for Post Traumatic Stress Disorder →

Sponsor

University Hospital, Brest

Who can join

18 and older, any sex, with Neurofibromatosis 1 or Diagnoses Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant genetic disorders. The aim of our study was to evaluate post-traumatic stress disorder (PTSD) in patients and their families following the disclosure of sporadic NF1. Diagnosis of NF1 was retained according to NIH criteria, familial forms were excluded. The French version of the Impact of Event Scale-Revised was used for the diagnosis of PTSD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.